<DOC>
	<DOCNO>NCT02109666</DOCNO>
	<brief_summary>The purpose study estimate retention rate Abatacept 24 month routine clinical practice every participate country depend treatment line .</brief_summary>
	<brief_title>Long Term Experience With Abatacept Routine Clinical Practice</brief_title>
	<detailed_description>Time Perspective : Other : Collection baseline data collect Abatacept IV initiation , prospectively retrospectively within maximum 3 month follow first administration . Other assessment collect follow period ( maximum 2 year patient ) Biospecimen Retention : None Retained excepted local sub study ( Spain ) sample DNA retain</detailed_description>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Male Female subject 18 year old Patients diagnosis establish moderate severe active RA ( per American College Rheumatology revise criterion , 1987 ) , physician 's discretion treat Abatacept accord SmPC Europe Product Monograph Canada ( initiate already treatment maximum 3 month ) baseline characteristic available Patients currently include interventional clinical trial RA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>